AIMT News and Press, Aimmune Therapeutics Inc. From 06/08/20

Aimmune Therapeutics ( AIMT +3.6% ) announces positive data from a follow-on study to its Phase 3 PALISADE trial of peanut allergy product Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp]. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the mov...

— After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Ra...

— Patients Report Treatment with PALFORZIA™ Is Convenient and Easy to Integrate into Daily Lives — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, toda...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41 st Annual G...

-- Important Data on Psychosocial Burden of Peanut Allergy on Children and Caregivers Also to be Presented -- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will pr...

-- Study highlights need to address varying levels of effective disease management, and the associated feelings of uncertainty, stress and isolation across eight European countries – -- Country-specific data show German respondents experience highest levels of anxiety, more than...

Aimmune Therapeutics (AIMT) is a newly commercial-stage biopharma developing a line of drugs designed to desensitize patients with common food allergies. Aimmune's first drug, Palforzia, was approved by the FDA to treat peanut allergies at the end of January 2020 and had just gotten out on the...

"I refuse to answer that question on the grounds that I don't know the answer. " - Douglas Adams The market is starting the new trading week on the right foot today. Investors are encouraged by more economies restarting, progress on the Covid-19 containment front and the latest vaccine n...

This January, the U.S. Food and Drug Administration (FDA) approved the first biologic for the treatment of peanut allergies in children and adolescents. The drug is called Palforzia and is marketed by Aimmune Therapeutics (NASDAQ: AIMT) . Expectations for Palforzia are high, as many analysts...

Genfit SA (NASDAQ: GNFT )  -67%  after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...